NFKB1 and breast cancer: We have found that in MCF7 and ZR-70-35 human mammary tumor cells the protective effect of Dex was compromised in the presence of 2.5 μM of Bay-117082, a pharmacological inhibitor of NF-κB activation (data not shown).